HCHTOG1906 Trial: Sequential vs. Concurrent Immunochemotherapy for Esophageal Cancer

A randomized controlled phase 2 trial enrolled 70 patients with locally advanced esophageal squamous cell carcinoma from July 2019 to June 2023. The dataset likely contains results comparing sequential versus concurrent administration of chemotherapy and PD-1 inhibitor toripalimab, including pathological complete remission rates, adverse events, and survival outcomes. Yan Zheng authored this trial data, published under a CC-BY-4.0 license.

Use Cases

• Compare pathological complete remission rates between sequential and concurrent treatment regimens based on the pCR outcome.
• Analyze the safety profile of different administration sequences based on reported treatment-related adverse events.
• Evaluate survival outcomes like overall survival and disease-free survival between the two treatment groups.
• Associate specific adverse events like nausea and diarrhea with the concurrent treatment strategy.

Strengths

• Data originates from a prospective, randomized controlled phase 2 trial with 70 enrolled patients.
• Results include specific rates: overall pCR rate of 22.2% and grade 3–5 TRAE incidence of 14.2%.
• The trial has a defined time range from July 2019 to June 2023.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 32.4 KB, indicating limited scope.

Provenance

Source

figshare

Collection Method

Data collected from a randomized, controlled, open-label, phase 2 clinical trial.

Time Range

July 2019 to June 2023

Freshness

Last updated 2026-05-07 04:37:15; freshness should be verified.